AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9831973 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin
Number of subjects: 100
Study 8208098 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyropol (thyroid-releasing hormone film)
Number of subjects: 0
Study 2734721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole administered by one daily IV infusion at 20 mg/kg
Number of subjects: 12
Study 2734721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole administered by two daily IV infusions at 20 mg/kg
Number of subjects: 12
Study 31948990 — intervention group
Group type: EXPERIMENTAL
Intervention: TKR plus 12 weeks of supervised non-surgical treatment (exercise, education, diet, insoles and pain medication)
Number of subjects: 100
Study 31948990 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment alone
Number of subjects: 100
Study 31948990 — intervention group
Group type: EXPERIMENTAL
Intervention: TKR plus non-surgical treatment
Number of subjects: 100
Study 30900905 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal dissolution test with polymer coatings (Surelease:Opadry at 8, 12, and 16% weight gain; Opadry EC at 4, 6, and 8% weight gain; Kollicoat Smartseal 100P at 10% weight gain)
Number of subjects: 0
Study 30900905 — intervention group
Group type: COMPARATOR
Intervention: USP I (basket) dissolution test
Number of subjects: 0
Study 30900905 — intervention group
Group type: EXPERIMENTAL
Intervention: Kollicoat Smartseal 100P coating
Number of subjects: 0
Study 30900905 — intervention group
Group type: EXPERIMENTAL
Intervention: Surelease:Opadry coating
Number of subjects: 0
Study 27636178 — intervention group
Group type: EXPERIMENTAL
Intervention: Motionless ultrasonic toothbrush
Number of subjects: 25
Study 27636178 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 25
Study 27636178 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study 25010354 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert Program for Self‐Regulation® (TXT)
Number of subjects: 25
Study 25010354 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control (DTC)
Number of subjects: 25
Study 23785019 — intervention group
Group type: EXPERIMENTAL
Intervention: udenafil 100 mg
Number of subjects: 118
Study 21083516 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin T (40 mg daily for 7 days)
Number of subjects: 20
Study 21083516 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin R (40 mg daily for 7 days)
Number of subjects: 20
Study 21083516 — intervention group
Group type: COMPARATOR
Intervention: Both LMWHs (T and R)
Number of subjects: 20
Study 19299636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 90
Study 19299636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17971525 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐cis‐RA and alpha‐tocopherol
Number of subjects: 225
Study 17971525 — intervention group
Group type: EXPERIMENTAL
Intervention: 9‐cis‐RA
Number of subjects: 225
Study 17971525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 15534051 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 35
Study 11205424 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections (two injections separated by 15 min)
Number of subjects: 20
Study 9272133 — intervention group
Group type: COMPARATOR
Intervention: CHOP (standard therapy)
Number of subjects: 0
Study 9272133 — intervention group
Group type: EXPERIMENTAL
Intervention: m-BACOD (third-generation regimen)
Number of subjects: 0
Study 9272133 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM (third-generation regimen)
Number of subjects: 0
Study 9272133 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOP-B (third-generation regimen)
Number of subjects: 0
Study 8511091 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCV 2 injections (days 0 and 28)
Number of subjects: 312
Study 8511091 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCV 3 injections (days 0, 7, and 28)
Number of subjects: 312
Study 8511091 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRV 2 injections (days 0 and 28)
Number of subjects: 312
Study 8511091 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRV 3 injections (days 0, 7, and 28)
Number of subjects: 312
Study 8511091 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose at 1 year
Number of subjects: 312
Study 3493614 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg X kg‐1
Number of subjects: 120
Study 3493614 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 5 mg X kg‐1
Number of subjects: 120
Study 3493614 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 120
Study 3493614 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 120
Study 3493614 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and Thiopentone
Number of subjects: 120
Study 28586524 — intervention group
Group type: COMPARATOR
Intervention: Experiential self-focus
Number of subjects: 80
Study 28586524 — intervention group
Group type: COMPARATOR
Intervention: Analytic self-focus
Number of subjects: 80
Study 27417045 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory evoked magnetic fields (SEFs) recorded following median nerve stimulation with single and double pulses
Number of subjects: 0
Study 27417045 — intervention group
Group type: COMPARATOR
Intervention: Control participants (not specified)
Number of subjects: 0
Study 26522104 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive prenatal test (NIPT) using Illumina HiSeq massively parallel sequencing platform
Number of subjects: 917
Study 24199979 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated yoga
Number of subjects: 96
Study 24199979 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal exercises (Control)
Number of subjects: 96
Study 20526530 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine plus 100 microg sodium‐selenite (group B)
Number of subjects: 49
Study 20526530 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine alone (group A)
Number of subjects: 49
Study 20526530 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine plus 200 microg sodium‐selenite (group C)
Number of subjects: 49
Study 18212711 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength-training group (heavy loads: 80% to 98% of 1-RM)
Number of subjects: 24
Study 18212711 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal velocity-training group (light loads: 25% to 50% of 1-RM)
Number of subjects: 24
Study 18212711 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 16377282 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning intake of atorvastatin
Number of subjects: 0
Study 16377282 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening intake of atorvastatin
Number of subjects: 0
Study 14645783 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET)
Number of subjects: 149
Study 14645783 — intervention group
Group type: COMPARATOR
Intervention: Active Informational Control (HIV-Info)
Number of subjects: 149
Study 14645783 — intervention group
Group type: COMPARATOR
Intervention: Waiting-List Control (WLC)
Number of subjects: 149
Study 11314241 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud bath treatment (group A)
Number of subjects: 37
Study 11314241 — intervention group
Group type: COMPARATOR
Intervention: Bath treatment alone (group B)
Number of subjects: 37
Study 9086543 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage
Number of subjects: 186
Study 9086543 — intervention group
Group type: COMPARATOR
Intervention: Open drainage
Number of subjects: 186
Study 9086543 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 186
Study 8168879 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed nailing (RN; n = 11)
Number of subjects: 30
Study 8168879 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreamed nailing (UN; n = 11)
Number of subjects: 30
Study 8168879 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation (EF; n = 8)
Number of subjects: 30
Study 8168879 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpulmonary TXB2-clearance
Number of subjects: 30
Study 8168879 — intervention group
Group type: EXPERIMENTAL
Intervention: TXB2 and PGF2 alpha
Number of subjects: 30
Study 8168879 — intervention group
Group type: EXPERIMENTAL
Intervention: Early fracture stabilisation
Number of subjects: 30
Study 3295573 — intervention group
Group type: EXPERIMENTAL
Intervention: Amizepin POLFA
Number of subjects: 10
Study 3295573 — intervention group
Group type: COMPARATOR
Intervention: Tegretol GEIGY
Number of subjects: 10
Study 30971133 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair of the pronator quadratus (PQ) muscle after volar plating
Number of subjects: 0
Study 30971133 — intervention group
Group type: COMPARATOR
Intervention: Nonrepair of the pronator quadratus (PQ) muscle after volar plating
Number of subjects: 0
Study 31626990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous reslizumab 3.0 mg/kg every 4 weeks for 52 weeks
Number of subjects: 953
Study 31626990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 953
Study 30509675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol (2 g) administered intravenously three times daily for 7-14 days
Number of subjects: 452
Study 30509675 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin (1 g each) administered intravenously three times daily for 7-14 days
Number of subjects: 452
Study 30509675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol (2 g)
Number of subjects: 452
Study 30509675 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin (1 g each)
Number of subjects: 452
Study 28076940 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso sorbide mononitrate (ISMN) 60 mg sustained release, self-administered vaginally every other day for five doses
Number of subjects: 144
Study 28076940 — intervention group
Group type: COMPARATOR
Intervention: Pyridoxine 10 mg (control)
Number of subjects: 144
Study 28076940 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso sorbide mononitrate (ISMN)
Number of subjects: 144
Study 22257581 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. 1 mg tolvaptan
Number of subjects: 14
Study 22257581 — intervention group
Group type: EXPERIMENTAL
Intervention: oral 30 mg tolvaptan
Number of subjects: 14
Study 22257581 — intervention group
Group type: COMPARATOR
Intervention: i.v. placebo
Number of subjects: 14
Study 20378094 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 0
Study 20378094 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 0
Study 20378094 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 0
Study 20378094 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy
Number of subjects: 0
Study 18190618 — intervention group
Group type: EXPERIMENTAL
Intervention: Auxiliary covariates adjustment
Number of subjects: 0
Study 18190618 — intervention group
Group type: COMPARATOR
Intervention: Standard analyses
Number of subjects: 0
Study 16201207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention activities during pregnancy
Number of subjects: 175
Study 16201207 — intervention group
Group type: COMPARATOR
Intervention: Higher Fagerström test score
Number of subjects: 175
Study 11208541 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal lipid perfusion at 1.5 kcal/min
Number of subjects: 9
Study 11208541 — intervention group
Group type: COMPARATOR
Intervention: Saline perfusion
Number of subjects: 9
Study 11208541 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (10 microg/kg iv)
Number of subjects: 9
Study 11208541 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate and protein perfusion
Number of subjects: 9
Study 11208541 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal lipid perfusion at 3 kcal/min
Number of subjects: 9
Study 10023473 — intervention group
Group type: EXPERIMENTAL
Intervention: New through-the-eyelid technique for axial length measurement using 'A' scan ultrasound
Number of subjects: 0
Study 7852604 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD with saccadic eye movements
Number of subjects: 6
Study 7852604 — intervention group
Group type: COMPARATOR
Intervention: EMD without saccadic eye movements (control)
Number of subjects: 6
Study 2903727 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 6
Study 2903727 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (15 mg)
Number of subjects: 6
Study 2903727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8514071 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (mean dose in vasovagal group)
Number of subjects: 223
Study 8514071 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (mean dose in control group)
Number of subjects: 223
Study 8514071 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe diverticulosis (vasovagal group)
Number of subjects: 223
Study 8514071 — intervention group
Group type: COMPARATOR
Intervention: Moderate to severe diverticulosis (control group)
Number of subjects: 223
Study 8514071 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical intervention required (vasovagal group)
Number of subjects: 223
Study 392375 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: decontaminated by nonabsorbable antibiotics in strict reverse isolation
Number of subjects: 60
Study 392375 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: isolated only
Number of subjects: 60
Study 392375 — intervention group
Group type: COMPARATOR
Intervention: Group C: treated under routine hospital conditions
Number of subjects: 60
Study 392375 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 60
Study 392375 — intervention group
Group type: COMPARATOR
Intervention: Group C
Number of subjects: 60
Study 30645611 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved-tip DLT (135 degree angle)
Number of subjects: 1427
Study 30645611 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard DLT without bent tip)
Number of subjects: 1427
Study 28116314 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 43
Study 28116314 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 43
Study 28116314 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 43
Study 26523663 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury-Prevention Program (IPP)
Number of subjects: 89
Study 26523663 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Warm-Up (DWU)
Number of subjects: 89
Study 26523663 — intervention group
Group type: COMPARATOR
Intervention: Static Warm-Up (SWU)
Number of subjects: 89
Study 23635998 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 20
Study 23635998 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 20
Study 21461596 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1) infusion (2.5 ng/kg/min) for 4 weeks
Number of subjects: 11
Study 21461596 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) for 4 weeks
Number of subjects: 11
Study 19717964 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 0
Study 17198774 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg orally the day before and the morning of the operation, a bolus of 150 mg/kg of intravenous N-acetylcysteine before skin incision, followed by perfusion at 12.5 mg x kg(‐1) x h(‐1) over 24 hours; n = 50)
Number of subjects: 100
Study 17198774 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 50)
Number of subjects: 100
Study 17198774 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 100
Study 17198774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 14987884 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided treatment (n=124)
Number of subjects: 243
Study 14987884 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=119)
Number of subjects: 243
Study 14987884 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 243
Study 11478788 — intervention group
Group type: EXPERIMENTAL
Intervention: N(omega)-carboxymethyl-arginine (CMA) in diabetic serum proteins
Number of subjects: 0
Study 11478788 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control serum proteins
Number of subjects: 0
Study 9764348 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin/Aspirin (H/A) alone
Number of subjects: 687
Study 9764348 — intervention group
Group type: COMPARATOR
Intervention: Heparin/Aspirin (H/A) not administered
Number of subjects: 687
Study 9764348 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin/Aspirin (H/A) with Intravenous Immunoglobulin G (IVIg)
Number of subjects: 687
Study 7924720 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic incontinence
Number of subjects: 23
Study 7924720 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic incontinence
Number of subjects: 23
Study 7924720 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 7924720 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sphincter defect
Number of subjects: 23
Study 7924720 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with idiopathic incontinence
Number of subjects: 23
Study 3276257 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms budesonide per day
Number of subjects: 30
Study 3276257 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms budesonide per day
Number of subjects: 30
Study 31611626 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional pediatric scheme (for fast responders with MRD < 0.1% on day 29)
Number of subjects: 278
Study 31611626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive block-based chemotherapy (for slow responders with MRD > 0.1% on day 29)
Number of subjects: 278
Study 31611626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive block-based chemotherapy
Number of subjects: 278
Study 31611626 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (both arms)
Number of subjects: 278
Study 31611626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive block therapy
Number of subjects: 278
Study 30852574 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat
Number of subjects: 252
Study 30852574 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin (Control)
Number of subjects: 252
Study 30852574 — intervention group
Group type: COMPARATOR
Intervention: Epoetin (Control)
Number of subjects: 252
Study 28340289 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC)
Number of subjects: 53
Study 28340289 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 53
Study 26108190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide 400 mg/day for 8 days
Number of subjects: 53
Study 23539322 — intervention group
Group type: EXPERIMENTAL
Intervention: Asha‐Life (AL) intervention delivered by HIV‐trained village women (Asha)
Number of subjects: 68
Study 23539322 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 68
Study 21699802 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA and Methotrexate (MTX)
Number of subjects: 29
Study 21699802 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA and Colchicine
Number of subjects: 29
Study 18374614 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg once daily for 28 days
Number of subjects: 37
Study 18374614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 16869482 — intervention group
Group type: EXPERIMENTAL
Intervention: KES parenting training with behaviour exercises
Number of subjects: 0
Study 16869482 — intervention group
Group type: COMPARATOR
Intervention: KES parenting training without behaviour exercises
Number of subjects: 0
Study 16869482 — intervention group
Group type: COMPARATOR
Intervention: Alternative treatment (discussion of problems)
Number of subjects: 0
Study 12590404 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100-250 mg/day)
Number of subjects: 86
Study 12590404 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (100-250 mg/day)
Number of subjects: 86
Study 12590404 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 86
Study 12590404 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 86
Study 11465584 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug that may increase the probability of survival by 20%
Number of subjects: 350
Study 11465584 — intervention group
Group type: EXPERIMENTAL
Intervention: Other distributions (Gaussian, J shape, uniform)
Number of subjects: 350
Study 9587116 — intervention group
Group type: EXPERIMENTAL
Intervention: CYFRA 21‐1
Number of subjects: 179
Study 9587116 — intervention group
Group type: EXPERIMENTAL
Intervention: TPS
Number of subjects: 179
Study 9587116 — intervention group
Group type: EXPERIMENTAL
Intervention: TPS and CYFRA 21‐1
Number of subjects: 179
Study 9587116 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TPS and CYFRA 21‐1 positive
Number of subjects: 179
Study 9587116 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of TPS and CYFRA 21‐1
Number of subjects: 179
Study 9587116 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 179
Study 7821189 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoalbuminuric IDDM patients with normal glomerular filtration rate
Number of subjects: 39
Study 7821189 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM patients with hyperfiltration
Number of subjects: 39
Study 7821189 — intervention group
Group type: COMPARATOR
Intervention: Age and sex matched controls
Number of subjects: 39
Study 3054623 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 70
Study 3054623 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 70